Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236088 | 0.91 | DPP4 (0.36) | TGFBR1DPP4MEN1KMT2A | |
| SCHEMBL5234421 | 0.91 | DPP4 (0.39) | DPP4 | |
| Hydrochloric Acid SCHEMBL5231815 | 0.86 | DPP4 (0.43) | DPP4PDE5A | |
| SCHEMBL5237726 | 0.85 | DPP4 (0.36) | TGFBR1DPP4PPARAPDE5AMEN1 | |
| SCHEMBL5237311 | 0.84 | DPP4 (0.46) | DPP4 | |
| SCHEMBL5234400 | 0.84 | DPP4 (0.39) | DPP4PPARAMEN1KMT2A | |
| SCHEMBL5236363 | 0.84 | PDE5A (0.35) | TGFBR1DPP4SHMT2PPARAPDE5A | |
| SCHEMBL5240636 | 0.83 | XDH (0.37) | DPP4 | |
| SCHEMBL5237560 | 0.83 | GAA (0.39) | DPP4 | |
| SCHEMBL5231544 | 0.83 | SREBF2 (0.39) | TGFBR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | TGFBR1 509/4885DPP4 2/4885KDR 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.